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46% and 36% for HCV genotype 1 and 76% and 61% for geno-
type 2/3. The impact of predictability testing at 12 and 24 weeks
on the cost-effectiveness ratio was explored in the model. Quality
of life and costs were based on literature and on estimated UK
treatment patterns, respectively. Costs were discounted at 6%
and beneﬁts at 1.5%. RESULTS: In genotype 1 patients, pegin-
terferon alfa-2a (40KD)/ribavirin increases quality-adjusted life
expectancy (QALY) by 0.43 years compared to interferon alfa-
2b/ribavirin. The incremental cost per QALY gained is £5596.
In genotype 2/3 patients, peginterferon alfa-2a (40KD)/ribavirin
increases QALY by 0.65 years and is cost saving (dominant) to
the NHS. The incremental cost-effectiveness ratio for all geno-
types was £914. At a cost effectiveness threshold of £30,000
probabilistic sensitivity analysis demonstrated peginterferon
alfa-2a was the cost effective treatment strategy in 96% of the
simulations. CONCLUSIONS: In the UK setting, peginterferon
alfa-2a (40KD)/ribavirin is cost-effective compared with con-
ventional interferon alfa-2b/ribavirin for treatment of naive
adults with CHC in genotype 1 patients and a cost-saving/dom-
inant therapy in genotype 2/3 patients.
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OBJECTIVES: There are no studies carried out to date compar-
ing the cost of systemic fungal infection treatment with voricona-
zole and caspofungin. The aim of the study was to estimate the
in-hospital cost of voriconazole versus caspofungin, plus oral
continuation therapy (OCT), for the treatment of invasive
Candida and Aspergillosis infections in Spain. METHODS: A
cost-minimization analysis model was performed from the hos-
pital perspective in year 2004, as the same efﬁcacy was assumed.
Data on duration of treatment (intravenous + oral) and weight
of patients were obtained from a local study: The Fungcost study.
The incidence of drug-related adverse events was obtained from
published clinical trials. Only direct cost for each episode were
considered; medications (injectable and oral) at their hospital
selling prices, the cost stemming from a drug-related adverse
reactions treatment; and administration costs. Oral voriconazole
was considered as the OCT for voriconazole arm, and oral ﬂu-
conazol or itraconazol for caspofungin arm. Mean expected cost
and incremental cost were calculated. Univariate and bivariate
sensitivity analysis were carried out varying patient’s weight 
and intravenous treatment duration. RESULTS: The mean cost
expected per episode (mean weight 68.6Kg) was 6302.97€ (cost
of intravenous treatment 5798.33€) for voriconazole, and
7487.29€ (6982.65€) for caspofungin in the treatment of inva-
sive aspergillosis, with an incremental cost of 1184.32€. The
treatment of candidiasis showed a mean costs of 6154.82€ (cost
of intravenous treatment 5951.14€) and 7182.71€ (7169.49€),
respectively, with an incremental cost of 1027.89€. Results were
robust to any intravenous duration of treatment, and sensitive
to an increase of patient’s weight above 103.3Kg in aspergillo-
sis and 101.1Kg in candidiasis. CONCLUSIONS: Using costs
and treatments patterns of fungal infections in Spain, voricona-
zole is more cost-effective than caspofungin in the treatment 
of invasive candidiasis and aspergillosis for patients below
101.1/103.3 kilograms, respectively.
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OBJECTIVES: To estimate costs and beneﬁts of a preventive
anti-inﬂuenza vaccination in a group of employees of ULSS 17
(an public health care district), in order to deﬁne a scheme of
cost-beneﬁt analysis to be used for other strategies of vaccina-
tion and in other contexts. METHODS: In an observational
study conducted from December 2002 to April 2003, 107
employees (about 5% of the whole staff of ULSS 17), who vol-
untarily underwent the vaccination, were compared with 107
non-vaccinated employees working in the same context and
matched for age, gender and working category. The outcome was
evaluated by checking records from the personnel department
about absence from work and related causes, including inﬂuenza.
Costs and beneﬁts of the anti-inﬂuenza vaccination from the
ULSS point of view were subsequently calculated. RESULTS:
Among vaccinated people absences from work were 23% less
than among non-vaccinated and working days lost were 30%
less than non vaccinated employees. The ratio between the ben-
eﬁts of the vaccination strategy (less working days lost) and its
cost was 4.2. The convenience emerges also through the sensi-
tivity analysis, which took in consideration the mean cost of a
working day for the enrolled employees, it showed that the cost-
beneﬁt ratio range from 4.5 to 11.7. CONCLUSIONS: The
results of this study suggest that the implementation of the anti-
inﬂuenza vaccination strategy in ours sample of working people
was cost saving. The cost-beneﬁt analysis used in this study could
also be used for other vaccination strategy and in other contexts.
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OBJECTIVE: In our study we aimed to assess and compare the
cost-effectiveness of sepsis treatment with and without Activated
Protein C in Hungary for the year 2002. METHODS: To calcu-
late the average efﬁciency of treatment of a septic patient in ICU
in Hungary we constructed a model. This model was made up
of three parts. In the ﬁrst part, we deﬁned a septic patient cohort
based on the age and gender distribution of all the septic cases
treated in ICU in Hungary in 2001. This patient cohort entered
into the second part of the model where we developed a time
dependent Markov model to describe and analyse the route of
Hungarian septic cases through a 28-day-long period. We
deﬁned three Markovian states: survival in ICU, leaving ICU or
the hospital alive, and death in or out of ICU. Transfer proba-
bilities were deﬁned for each of the 28 days on the basis of data
collected for all septic events treated in ICUs in Hungary in 2001.
In the Activated Protein C (Xigris®) treatment arm the transfer
probabilities of the above-described model was modiﬁed on the
basis of results of a clinical study. In the third phase, patients’
life-long survival was modelled based on the average age-speciﬁc
life expectancy of the Hungarian. Survival of the septic patients
was corrected by a factor of 0.51 taken from the international
literature. Efﬁciency was calculated from societal viewpoint.
RESULTS: Average cost-effectiveness of sepsis treatment was
